| Steven | I live in London <a href=" http://www.hotelcalifornia.com/drug-abuse-of-prescription-drugs.html#mechanical ">beryl drugs ltd share price</a> Diagnoplex SA, a developer of molecular diagnostics for colon cancer and Debiopharm Diagnostics SA, part of the Swiss-based global biopharmaceutical group of companies Debiopharm Group(TM), with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that Diagnoplex has secured 1.3 million Swiss francs from a financing round led by Debiopharm. |
|